What is the recommended treatment regimen for uncomplicated gonorrhea, including dosing, alternatives for β‑lactam allergy, partner therapy, and follow‑up?

Gonorrhea Treatment Guidelines

Primary Treatment Recommendation

For uncomplicated gonorrhea of the cervix, urethra, rectum, and pharynx, administer ceftriaxone 500 mg intramuscularly as a single dose PLUS azithromycin 1 g orally as a single dose. 1, 2

This dual-therapy approach addresses both gonorrhea and presumptive chlamydial coinfection, which occurs in 20–50% of cases, while also serving as a strategy to delay emergence of cephalosporin resistance. 1

Rationale for Ceftriaxone 500 mg

• Ceftriaxone achieves a 99.1% cure rate for uncomplicated urogenital and anorectal infections, making it the most effective single-dose regimen available. 3, 1
• The dose was increased from 250 mg to 500 mg in 2020 to maintain a therapeutic reserve against emerging resistance patterns, even though no ceftriaxone-resistant strains have been reported in the United States. 1, 2
• Ceftriaxone provides sustained, high bactericidal blood levels and is the only reliably effective treatment for pharyngeal gonorrhea, which is significantly more difficult to eradicate than urogenital infections. 3, 1

Rationale for Dual Therapy with Azithromycin

• Azithromycin 1 g is preferred over doxycycline due to the convenience and compliance advantages of single-dose therapy, and because gonococcal resistance to tetracycline is substantially higher than to azithromycin. 1
• If chlamydial infection has been excluded by testing, doxycycline 100 mg orally twice daily for 7 days may be substituted for azithromycin. 2
• Never use azithromycin 1 g as monotherapy for gonorrhea—it achieves only 93% efficacy and promotes rapid resistance development. 3, 1

---

Alternative Regimens

When Ceftriaxone Is Unavailable

Administer cefixime 400 mg orally as a single dose PLUS azithromycin 1 g orally as a single dose, with mandatory test-of-cure at one week. 1

• Cefixime achieves only a 97.4% overall cure rate (compared to 99.1% for ceftriaxone) and provides lower, less sustained bactericidal levels. 3, 1
• Cefixime cures only 78.9% of pharyngeal infections, making it unreliable for this site. 1
• Test-of-cure is mandatory because of rising cefixime MICs and documented treatment failures in Europe. 1

For Severe Cephalosporin Allergy

Administer azithromycin 2 g orally as a single dose, with mandatory test-of-cure at one week. 1

• This regimen has lower efficacy (approximately 93%) and causes significant gastrointestinal distress. 3, 1
• Spectinomycin 2 g intramuscularly is an alternative for urogenital infections but achieves only 52% cure for pharyngeal gonorrhea and should be avoided when pharyngeal exposure is possible. 3, 1
• For pregnant patients with severe cephalosporin allergy, use spectinomycin 2 g intramuscularly plus azithromycin 1 g orally. 1

---

Contraindicated Medications

Fluoroquinolones Are Absolutely Prohibited

Never use fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin) for gonorrhea treatment due to widespread resistance, despite historical cure rates exceeding 99.8%. 3, 1

• Quinolones are also contraindicated in pregnant or nursing women and in persons ≤17 years of age based on animal safety data. 3, 1

Other Contraindicated Approaches

• Do not use azithromycin 1 g alone—insufficient efficacy and rapid resistance emergence. 3, 1
• Do not use cefixime without azithromycin or doxycycline—this violates dual-therapy recommendations. 1

---

Site-Specific Considerations

Pharyngeal Gonorrhea

Pharyngeal infections are markedly more difficult to eradicate than urogenital or anorectal infections. 3, 1

• Ceftriaxone 500 mg intramuscularly is the only reliably effective treatment for pharyngeal gonorrhea. 1
• Oral cephalosporins (cefixime) cure only 78.9% of pharyngeal infections. 1
• Spectinomycin achieves only 52% cure for pharyngeal disease. 3, 1

Gonococcal Conjunctivitis

Administer ceftriaxone 1 g intramuscularly as a single dose PLUS a single saline eye lavage. 1

Disseminated Gonococcal Infection (DGI)

• Hospitalize the patient for initial therapy. 1
• Administer ceftriaxone 1 g intramuscularly or intravenously every 24 hours for 24–48 hours until clinical improvement, then switch to oral therapy to complete a total of 7 days of treatment. 1
• Evaluate for endocarditis and meningitis as part of the assessment. 1
• For β-lactam allergy, spectinomycin 2 g intramuscularly every 12 hours is an alternative. 1

---

Special Populations

Pregnancy

Administer ceftriaxone 500 mg intramuscularly PLUS azithromycin 1 g orally as a single dose. 1

• Quinolones, tetracyclines, and doxycycline are absolutely contraindicated in pregnancy due to fetal safety concerns. 1
• If severe cephalosporin allergy is documented, use spectinomycin 2 g intramuscularly plus azithromycin 1 g orally. 1

Men Who Have Sex with Men (MSM)

Ceftriaxone is the only recommended treatment for MSM due to higher prevalence of resistant strains. 1

• Never use quinolones in MSM. 1
• Do not offer expedited partner therapy to MSM because of the high risk of undiagnosed coexisting STDs or HIV. 1

Patients with Recent Foreign Travel

Ceftriaxone 500 mg intramuscularly is the only recommended treatment due to increased risk of resistant strains. 1

---

Partner Management

Evaluation and Treatment of Sexual Partners

All sexual partners from the preceding 60 days must be evaluated and treated with the same dual-therapy regimen (ceftriaxone 500 mg IM + azithromycin 1 g PO), regardless of symptoms or test results. 3, 1

• If the index patient is symptomatic, treat all partners whose last sexual contact occurred ≤30 days before symptom onset. 3, 1
• If the index patient is asymptomatic, treat all partners whose last sexual contact occurred ≤60 days before diagnosis. 3, 1
• If the last sexual contact predates these windows, treat the most recent partner. 3, 1

Expedited Partner Therapy (EPT)

• EPT may be considered when partners cannot be linked to timely evaluation, using oral combination therapy (cefixime 400 mg plus azithromycin 1 g). 1
• Do not use EPT for MSM due to high risk of undiagnosed coexisting STDs or HIV. 1

Sexual Activity Restrictions

Patients must abstain from sexual intercourse until therapy is completed and both they and all partners are asymptomatic. 3, 1

---

Follow-Up and Test-of-Cure

Routine Follow-Up

Patients treated with the recommended ceftriaxone-based regimen do not need routine test-of-cure unless symptoms persist. 3, 1

• Consider retesting all patients at 3 months due to high reinfection risk (20–30%). 1

Mandatory Test-of-Cure Situations

Test-of-cure at one week is mandatory for:

• Patients treated with cefixime-based regimens (due to rising MICs and declining effectiveness). 1
• Patients treated with azithromycin 2 g monotherapy (due to lower efficacy). 1
• Patients treated with spectinomycin for suspected pharyngeal infection. 1

Persistent Symptoms After Treatment

If symptoms persist, obtain culture with antimicrobial susceptibility testing from all potentially infected sites. 3, 1

• Most post-treatment infections represent reinfection rather than treatment failure, indicating need for improved partner referral and patient education. 3, 1
• Report suspected treatment failures to local public health officials within 24 hours and consult an infectious disease specialist. 1

---

Treatment Failure Management

Suspected Ceftriaxone Treatment Failure

If treatment failure is suspected:

1. Obtain specimens for culture and antimicrobial susceptibility testing immediately. 1
2. Report the case to local public health officials within 24 hours. 1
3. Consult an infectious disease specialist. 1

Recommended salvage regimens include:

• Gentamicin 240 mg intramuscularly PLUS azithromycin 2 g orally (single dose). 1
• Ertapenem 1 g intramuscularly for 3 days. 1
• Spectinomycin 2 g intramuscularly PLUS azithromycin 2 g orally (single dose). 1

Note: Most ceftriaxone treatment failures involve the pharynx, not urogenital sites. Both spectinomycin and gentamicin have poor efficacy in the pharynx. 1

---

Additional Screening

Screen for syphilis by serology at the time of gonorrhea diagnosis. 3, 1

Co-test for HIV, as gonorrhea facilitates HIV transmission. 1

---

Common Pitfalls to Avoid

• Never use fluoroquinolones—widespread resistance renders them ineffective. 3, 1
• Never use azithromycin 1 g alone—insufficient efficacy and rapid resistance. 3, 1
• Never omit chlamydia treatment when chlamydial infection has not been excluded—coinfection occurs in 20–50% of cases. 1
• Do not assume oral cephalosporins are equivalent to ceftriaxone—they have inferior efficacy, especially for pharyngeal disease. 1
• Do not forget mandatory test-of-cure when using cefixime or azithromycin monotherapy. 1